AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34174903
Drug: Respiratory rate/DTF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Respiratory rate/DTF ratio measured at baseline and at 1, 4, 12, 24, 48, 72, and 96 hours of NIV treatment.
Trial: 34175021
Drug: Ciltacabtagene autoleucel
RxNorm normalized name: ciltacabtagene autoleucel
DrugBank: Ciltacabtagene autoleucel (DB16738)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciltacabtagene autoleucel (cilta-cel) infusion at a target dose of 0.75 × 10^6 cells/kg
Trial: 34175043
Drug: Adeno-associated virus-vectorized
RxNorm normalized name: Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2
DrugBank: Voretigene neparvovec (DB13932)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adeno-associated virus-vectorized gene therapies (gene replacement or antisense oligonucleotide-mediated pre-mRNA splicing modulation)
Trial: 34175043
Drug: Experimental therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental therapies using somatic cell gene editing
Trial: 34175582
Drug: Intramuscular magnesium
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular magnesium sulphate administered by community-based health workers (CHWs)
Trial: 34175582
Drug: Oral methyldopa
RxNorm normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral methyldopa administered by Community Health Extension Workers (CHEWs) and nurses
Trial: 34176021
Drug: Dose reduction
RxNorm normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose reduction or delay due to neuropathy (group 2)
Trial: 34176021
Drug: Discontinuation due
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation due to neuropathy (group 3)
Trial: 34176021
Drug: Completed treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Completed treatment without alteration (group 1)
Trial: 34176021
Drug: Clinician-assessed neuropathy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinician-assessed neuropathy severity at dose reduction or delay
Trial: 34176021
Drug: Patient-reported neuropathy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-reported neuropathy severity at cycle 4 for dose reduction or delay
Trial: 34176752
Drug: Treatment adherence
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment adherence and overall survival
Trial: 34177581
Drug: Lithium Carbonate;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium Carbonate; dosage and duration not available
Trial: 34177626
Drug: Nasal High
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal High Flow (NHF) at 25 L/min
Trial: 34178122
Drug: Subsequent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent chemotherapy (147 patients, 73.5%)
Trial: 34178122
Drug: Subsequent endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent endocrine therapy (53 patients, 26.5%)
Trial: 34178122
Drug: Subsequent therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent therapies after palbociclib
Trial: 34180037
Drug: Idasanutlin (QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idasanutlin (QD dosing)
Trial: 34180161
Drug: Overall ADHD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall ADHD medications
Trial: 34181697
Drug: High levels
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High levels of fecal IgA antibodies against Cryptosporidium Cp23 sporozoite protein at one year of life
Trial: 34181872
Drug: Antibody features
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody features towards VAR2CSA identified through machine learning techniques
Trial: 34182032
Drug: Heparin-bonded stent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-bonded stent grafts
Trial: 34183020
Drug: Regular use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular use of omega-3 fatty acid supplements (n=856)
Trial: 34183020
Drug: Non-users of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-users of omega-3 fatty acid supplements (n=348)
Trial: 34184326
Drug: Samples from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Samples from patients with concurrent de novo HLA DSAs
Trial: 34184441
Drug: Fimasartan-based antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan-based antihypertensive therapy
Trial: 34185020
Drug: Interprofessional medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interprofessional medication adherence program (IMAP) with regular motivational interviewing sessions and delivery of PKIs in electronic monitors
Trial: 34185020
Drug: Interprofessional medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interprofessional medication adherence program (IMAP)
Trial: 34185020
Drug: PKI pharmacokinetics
RxNorm normalized name: PKI-179
DrugBank: PKI-179 (DB13109)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PKI pharmacokinetics
Trial: 34185020
Drug: PKI dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PKI dosage adaptation
Trial: 34185084
Drug: Standard-care medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-care medications (triptans or over-the-counter medications)
Trial: 34185953
Drug: Blinatumomab (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinatumomab (9 μg/day for week 1, 28 μg/day for weeks 2-4, followed by 2 weeks of no treatment; 28 μg/day in subsequent cycles)
Trial: 34186262
Drug: Total bilirubin
RxNorm normalized name: bilirubin preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total bilirubin ≥1.93 mg/dL
Trial: 34187401
Drug: Copanlisib (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copanlisib (60 mg intravenous on days 1, 8, 15 for 6 cycles of 28 days) and Rituximab (375 mg/m2)
Trial: 34187831
Drug: Activities of
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activities of Daily Living (ADL) measured by modified Rankin Scale scores
Trial: 34187871
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (EVT) with concurrent intravenous (IV) alteplase
Trial: 34187871
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (EVT) only
Trial: 34188166
Drug: Serum PTX3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum PTX3 above 4.34 ng/mL
Trial: 34189178
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg) with loperamide
Trial: 34189178
Drug: Levofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (500 mg) with loperamide
Trial: 34189178
Drug: Rifaximin (1650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin (1650 mg) with loperamide
Trial: 34189178
Drug: Control (pre-antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (pre-antibiotic treatment)
Trial: 34189463
Drug: Bevacizumab 5
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 5 mg/kg every 2 weeks for 12 weeks
Trial: 34190375
Drug: Sunitinib (SUN)
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib (SUN) plus Evofosfamide (EVO) 340 mg/m
Trial: 34191201
Drug: Taxane- or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxane- or platinum-based chemotherapy
Trial: 34191621
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate (TU) at 225 mg twice daily
Trial: 34192154
Drug: SARS-CoV-2 antibody
RxNorm normalized name: SARS-CoV-2 antibody-based IVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 antibody testing using chemiluminescence assays (chemiluminescence immunoassay and electrochemiluminescence)
Trial: 34192154
Drug: Antiviral antibody
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral antibody titres
Trial: 34192989
Drug: LBSA0103 hyaluronic
RxNorm normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LBSA0103 hyaluronic acid injection
Trial: 34193096
Drug: Community-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based intervention consisting of a 20-25 min oral presentation in Urdu and Somali on cervical cancer and screening.
Trial: 34193595
Drug: Newer drugs
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Newer drugs targeting novel blood glucose-lowering pathways
Trial: 34193595
Drug: Traditional pharmacologic
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional pharmacologic therapies (insulin, metformin, sulfonylureas)
Trial: 34193595
Drug: Treatments targeting
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatments targeting incretin action, islet transplantation, generation of functional beta cells from stem cells
Trial: 34194721
Drug: Levothyroxine (L-T4)
RxNorm normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine (L-T4) therapy for 12 months
Trial: 34195252
Drug: Endobronchial administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endobronchial administration of autologous bone marrow mesenchymal stromal cells (BM-MSCs)
Trial: 34195471
Drug: Preoperative preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative preparation with Lugol's Solution (LS)
Trial: 34195471
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no preoperative preparation with LS)
Trial: 34195794
Drug: Low-molecular weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular weight heparin (LMWH) and/or low-dose aspirin (ASA)
Trial: 34195794
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (absence of LMWH/ASA)
Trial: 34196037
Drug: Entospletinib in
RxNorm normalized name: Entospletinib
DrugBank: Entospletinib (DB12121)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entospletinib in combination with obinutuzumab
Trial: 34196165
Drug: Tafasitamab (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafasitamab (12 mg/kg intravenously) plus Lenalidomide (25 mg orally)
Trial: 39527960
Drug: Betibeglogene autotemcel
RxNorm normalized name: betibeglogene autotemcel
DrugBank: Betibeglogene autotemcel (DB16900)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betibeglogene autotemcel (beti-cel) gene therapy
Trial: 34201806
Drug: Oral melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral melatonin (1 mg) plus zinc (10 mg) supplementation
Trial: 34206826
Drug: Cantrixil (TRX-E-002-1);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cantrixil (TRX-E-002-1); specific dosage and duration not mentioned.
Trial: 34208432
Drug: Long-term therapy
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term therapy with Statins and Acetyl Salicylic Acid
Trial: 34210826
Drug: SENTI-101 (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SENTI-101 (a preparation of bone marrow-derived mesenchymal stromal cells engineered to express IL12 and IL21)
Trial: 34210826
Drug: mSENTI-101 co-administered
RxNorm normalized name: CO
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mSENTI-101 co-administered with checkpoint inhibitors
Trial: 34211280
Drug: High-dosage inhaled
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dosage inhaled corticosteroids with additional controllers (HD ICS+)
Trial: 34211773
Drug: SBRT 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBRT 30 to 50 Gy in 5 fractions (median dose 40 Gy)
Trial: 34212814
Drug: Inappropriate medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inappropriate medication stopping
Trial: 34213732
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg lipegfilgrastim (single SC injection)
Trial: 34213962
Drug: Rivastigmine treatment
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine treatment for memory impairment after TBI
Trial: 34215024
Drug: NTLA-2001 (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTLA-2001 (0.1 mg/kg)
Trial: 34215024
Drug: NTLA-2001 (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTLA-2001 (0.3 mg/kg)
Trial: 34215319
Drug: SB cell
RxNorm normalized name: SB 224289
DrugBank: SB 224289 (DB17052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB cell treatment (1 × 10)
Trial: 34215319
Drug: SB cell
RxNorm normalized name: SB 224289
DrugBank: SB 224289 (DB17052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB cell treatment
Trial: 34215323
Drug: Mentalization-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentalization-based treatment for conduct disorder (MBT-CD)
Trial: 34215684
Drug: Voluntary daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voluntary daily noise monitoring intervention
Trial: 34215909
Drug: Asfotase alfa
RxNorm normalized name: Asfotase alfa
DrugBank: Asfotase alfa (DB09105)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Asfotase alfa treatment
Trial: 34216069
Drug: CRT-D therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRT-D therapy
Trial: 34216069
Drug: ICD implant
RxNorm normalized name: ICDMT
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ICD implant
Trial: 34216189
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy with corticosteroids and statins
Trial: 34216247
Drug: Budigalimab 250
RxNorm normalized name: Budigalimab
DrugBank: Budigalimab (DB16668)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budigalimab 250 mg intravenously Q2W
Trial: 34216247
Drug: Budigalimab 500
RxNorm normalized name: Budigalimab
DrugBank: Budigalimab (DB16668)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budigalimab 500 mg intravenously Q4W
Trial: 34216247
Drug: Budigalimab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budigalimab (both dosing regimens)
Trial: 34217109
Drug: Novel effective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel effective therapies targeting key signaling pathways in PAH
Trial: 34217426
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral PrEP (coformulated tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg)
Trial: 34218284
Drug: S antibodies
RxNorm normalized name: Immune Globulin (Human) containing high titers of West Nile virus antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S antibodies
Trial: 34218284
Drug: N antibodies
RxNorm normalized name: digoxin antibodies Fab fragments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N antibodies
Trial: 34222719
Drug: IONIS-AGT-L
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IONIS-AGT-L
Trial: 34222761
Drug: Monthly review
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly review meetings with staff and supervisors
Trial: 34222848
Drug: MVC-COV1901 5
RxNorm normalized name: MVC-COV1901
DrugBank: MVC-COV1901 (DB15854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVC-COV1901 5 μg
Trial: 34222848
Drug: MVC-COV1901 15
RxNorm normalized name: MVC-COV1901
DrugBank: MVC-COV1901 (DB15854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVC-COV1901 15 μg
Trial: 34222848
Drug: MVC-COV1901 25
RxNorm normalized name: MVC-COV1901
DrugBank: MVC-COV1901 (DB15854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVC-COV1901 25 μg
Trial: 34222849
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate and emtricitabine (2 pills on day 1 followed by 1 pill per day on days 2-7)
Trial: 34222847
Drug: Nitazoxanide (NTZ)
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitazoxanide (NTZ) 600 mg BID for seven days
Trial: 34223347
Drug: Vasopressin and
RxNorm normalized name: Vasopressin and analogues
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasopressin and Methylprednisolone (40 mg methylprednisolone and 20 IU vasopressin, with additional doses of vasopressin after each adrenaline dose for a maximum of four doses)
Trial: 34223403
Drug: Glucose metabolism
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose metabolism via glycolysis
Trial: 34223403
Drug: Glucose metabolism
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose metabolism
Trial: 34223402
Drug: RH5.1 recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RH5.1 recombinant protein vaccine
Trial: 34224261
Drug: Infusion Centers
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion Centers (ICs)
Trial: 34224432
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with BPA
Trial: 34224432
Drug: BPA alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPA alone or in combination with PEA or medical therapy
Trial: 34529762
Drug: BNT162b2 vaccine
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 vaccine (2 doses)
Trial: 34224684
Drug: XC001 gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: XC001 gene therapy
Trial: 34226282
Drug: Control saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control saline infusion (SC)
Trial: 34227124
Drug: Hydroxyurea (hydroxycarbamide)
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing starting at predicted maximum tolerated dose (MTD)
Trial: 34227790
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training (aerobic and resistance training) for 12 weeks, twice weekly
Trial: 34227849
Drug: Referral processes
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referral processes to clinic-community partnership programs for childhood obesity treatment
Trial: 34229186
Drug: Standardized antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized antidepressant treatment protocol for 16 weeks
Trial: 34229268
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 200 mg PM
Trial: 34229268
Drug: Three daily
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three daily dose of 67 mg PM
Trial: 34229325
Drug: Support to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Support to access downstream treatment
Trial: 34229330
Drug: Nonnucleoside reverse
RxNorm normalized name: OraVerse
DrugBank: Phentolamine (DB00692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonnucleoside reverse transcriptase inhibitor resistance
Trial: 34229330
Drug: Nucleoside reverse
RxNorm normalized name: Non-nucleoside reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleoside reverse transcriptase inhibitor resistance
Trial: 34230007
Drug: MDM2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MDM2 inhibitor ALRN-6924
Trial: 34230007
Drug: MDM2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MDM2 inhibitors
Trial: 34232223
Drug: Proprotein convertase
RxNorm normalized name: Proprotein convertase 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proprotein convertase subtilisin/kexin 9 inhibitors
Trial: 34232493
Drug: Nebulized glycopyrrolate
RxNorm normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized glycopyrrolate (GLY) 25 µg
Trial: 34232694
Drug: Standard-Dose CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-Dose CT
Trial: 34233259
Drug: Key radiomic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Key radiomic features before and after neoadjuvant chemotherapy